Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Pays $15 Million for China Rights to Electric Field Therapy for Brain Cancer

publication date: Sep 12, 2018

Zai Lab acquired greater China rights to Novocure 's Optune, paying $15 million upfront. Optune is a therapy that uses electric fields, called Tumor Treating Fields, that are tuned to specific frequencies to treat cancer. The fields disrupt cell division, inhibiting tumor growth. The treatment is approved to treat brain cancer. In addition to the upfront payment, Zai will also make development, regulatory and commercial milestone payments, plus royalties. Zai will help Novocure by accelerating patient enrollment for new indications. More details....

Stock Symbols: (NSDQ: ZLAB) (NSDQ: NVCR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.